Companies Cerevel Therapeutics Holdings

Cerevel Therapeutics (CERE): executive pay, fiscal 2022

Free brief. Every figure links to the company’s own filing.

Cerevel Therapeutics Holdings no longer files a proxy statement; its last pay data is FY2022.

All products and prices

CEO total pay$11,225,426CEO N. Anthony Coles · source

Say-on-pay support99.59%Latest vote · source

CEO vs. named peers86th pct.Of 14 peer CEOs

CEO pay ratio35:1To the median employee

CEO pay, last three years

$2,741,999FY2020
$8,108,335FY2021
$11,225,426FY2022

CEO total pay was $11,225,426 in fiscal 2022, up from $8,108,335 in fiscal 2021.

FY2022: salary $642,735 · bonus $0 · stock awards $0 · option awards $10,085,985

Frequently asked questions

Who was the highest-paid executive at Cerevel Therapeutics Holdings in fiscal 2022?

As disclosed, N. Anthony Coles (Chief Executive Officer and Chairperson of the Board of Directors) was the highest-paid executive at Cerevel Therapeutics Holdings in fiscal 2022, with total compensation of $11,225,426.

How does Cerevel Therapeutics Holdings's chief executive pay compare to its disclosed peer group?

As disclosed, N. Anthony Coles's total compensation ranked at the 86th percentile of Cerevel Therapeutics Holdings's disclosed peer group.

What is Cerevel Therapeutics Holdings's CEO-to-median employee pay ratio?

As disclosed, Cerevel Therapeutics Holdings's CEO-to-median employee pay ratio was 35:1.

How did shareholders vote on Cerevel Therapeutics Holdings's executive compensation?

As disclosed, 99.59% of shareholders supported Cerevel Therapeutics Holdings's executive compensation in the latest say-on-pay vote.

How much does Cerevel Therapeutics Holdings spend in total on board compensation for fiscal 2022?

As disclosed, Cerevel Therapeutics Holdings reported total board compensation of $607,246 for fiscal 2022.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
N. Anthony Coles	$642,735	$0	$0	$10,085,985	$496,706	$0	$0	$11,225,426
Chief Executive Officer and Chairperson of the Board of Directors
Raymond Sanchez	498,120	0	0	3,999,979	288,711	0	18,300	4,805,110
Chief Medical Officer
John Renger	482,052	0	0	3,999,979	279,398	0	18,300	4,779,729
Chief Scientific Officer
Abraham Ceesay	511,651	0	0	2,849,987	296,553	0	18,300	3,676,491
President
Mark Bodenrader	337,712	0	499,994	587,480	140,154	0	18,300	1,583,640
Interim Chief Financial Officer; Senior Vice President, Finance and Chief Accounting Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2022 total	FY2021 total	FY2020 total	Δ FY2021→2022
N. Anthony Coles	$11,225,426	$8,108,335	$2,741,999	↑ +3,117,091
Raymond Sanchez	4,805,110	3,416,287	1,771,937	↑ +1,388,823
John Renger	4,779,729	3,093,750	1,845,075	↑ +1,685,979
Abraham Ceesay	3,676,491	5,276,631	—	↓ −1,600,140
Mark Bodenrader	1,583,640	1,312,994	—	↑ +270,646

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation programs are designed to motivate, retain and reward high-performing executives for their long-term value creation for the Company. While we consider several factors in our pay structure, we are guided by the following core philosophies and principles: Mission and Patient Focused, Pay for Performance, Alignment with Stockholders, Simplicity and Transparency, Program Consistency.

CEO STI target (% of salary)	60%
CEO LTI target (% of salary)	—
Independent consultant	Pay Governance LLC
Clawback policy	True
Anti-hedging	True
Anti-pledging	True

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2022

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Mark Bodenrader	OPTION	2022-02-09	—	—	24,800	—	$587,480
Mark Bodenrader	RSU	2022-06-01	—	—	18,932	—	499,994
Raymond Sanchez	OPTION	2022-02-09	—	—	168,856	—	3,999,979
Abraham Ceesay	OPTION	2022-02-09	—	—	120,310	—	2,849,987
John Renger	OPTION	2022-02-09	—	—	168,856	—	3,999,979
N. Anthony	OPTION	2022-02-09	—	—	425,772	—	10,085,985

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Mark Bodenrader	$499,994	$0	$587,480	0.0%
Raymond Sanchez	0	0	3,999,979	0.0%
Abraham Ceesay	0	0	2,849,987	0.0%
John Renger	0	0	3,999,979	0.0%
N. Anthony	0	0	10,085,985	0.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2022

Executive	Award	Shares unvested	Exercise price	Market value unvested
Mark Bodenrader	Option	3,636	10.28	—
Raymond Sanchez	Option	3,878	10.28	—
Mark Bodenrader	Option	10,907	3.5	—
Raymond Sanchez	Option	11,635	3.5	—
John Renger	Option	13,358	10.28	—
Mark Bodenrader	RSU	18,932	—	597,115
Mark Bodenrader	Option	24,800	30.36	—
Mark Bodenrader	Option	32,723	9.88	—
John Renger	Option	40,073	3.5	—
Mark Bodenrader	Option	48,750	12.7	—
John Renger	Option	58,901	9.88	—
Raymond Sanchez	Option	65,445	9.88	—
N. Anthony Coles	Option	98,168	9.88	—
Abraham Ceesay	Option	120,310	30.36	—
John Renger	Option	134,160	12.7	—
Raymond Sanchez	Option	150,929	12.7	—
Raymond Sanchez	Option	168,856	30.36	—
John Renger	Option	168,856	30.36	—
Abraham Ceesay	Option	288,166	13.17	—
N. Anthony Coles	Option	396,888	12.7	—
N. Anthony Coles	Option	425,772	30.36	—

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Norbert Riedel, Ph.DIndependent · Lead Independent Director · Audit · Science and Technology (Chair)	$134,582	$0	$427,984	—	$0	$562,566
Gabrielle Sulzberger, J.D., M.B.AIndependent · Audit (Chair) · Nominating/Governance	82,999	0	427,984	—	0	510,983
Marijn Dekkers, Ph.DIndependent · Compensation · Nominating/Governance	71,333	0	427,984	—	0	499,317
Doug Giordano, M.B.AIndependent · Audit · Compensation (Chair)	69,166	0	427,984	—	0	497,150
Christopher Gordon, M.B.AIndependent · Nominating/Governance (Chair)	69,166	0	427,984	—	0	497,150
Adam Koppel, M.D., Ph.DIndependent · Compensation · Science and Technology	65,000	0	427,984	—	0	492,984
Ruth McKernan, Ph.D., CBE, FMedSciIndependent · Science and Technology	57,500	0	427,984	—	0	485,484
Deval Patrick, J.DIndependent · Compensation	57,500	0	427,984	—	0	485,484
Suneet Varma, M.B.ANot independent · Science and Technology · Newly elected	0	0	0	—	0	0
Deborah Baron, M.B.AIndependent · Nominating/Governance	0	0	0	—	0	0
N. Anthony Coles, M.DEmployee director · Board Chair	0	0	0	—	0	0
Morris Birnbaum, M.D., Ph.DNot independent · Departed during FY	0	0	0	—	0	0

Board fee structure and ownership guideline

Annual cash retainer	$50,000
Annual equity retainer	$428,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	15,000 / 15,000 / 15,000
Stock ownership guideline	3x annual cash retainer

Total cost of the board

Component	FY2022
Cash retainers and fees	$607,246
Equity awards (grant-date value)	$0
All other compensation	$0
Total cost of the board	$607,246

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Cerevel Therapeutics as a peer

Companies that benchmark against CERE

5 companies name CERE as a compensation peer

Each company listed discloses CERE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CERE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2022

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

FATE Fate TherapeuticsNBIX Neurocrine BiosciencesNTLA Intellia TherapeuticsKRTX Karuna TherapeuticsALLO Allogene TherapeuticsRCUS Arcus BiosciencesAXSM Axsome TherapeuticsBBIO BridgeBio PharmaDNLI Denali TherapeuticsSAGE Sage TherapeuticsARVN ArvinasALEC AlectorREPL Replimune GroupZYME Zymeworks

Peer reciprocity

The companies Cerevel Therapeutics Holdings names as compensation peers that name it back in their own disclosed peer groups.

Karuna Therapeutics (KRTX)²²¹Sage Therapeutics (SAGE)²²²

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	BridgeBio Pharma	2025	Neil Kumar	$1,044,000	$10,606,275	$1,874,992	$0	$14,944,585
2	Neurocrine Biosciences	2025	Kyle Gano	920,000	5,750,023	5,750,006	0	13,448,935
3	Cerevel Therapeutics Holdings	2022	N. Anthony Coles	642,735	0	10,085,985	496,706	11,225,426
4	Karuna Therapeutics	2022	Steven Paul	700,000	0	9,905,953	609,000	11,224,103
5	Axsome Therapeutics	2025	Herriot Tabuteau	835,000	5,533,554	2,833,237	876,750	10,283,492
6	Arcus Biosciences	2025	Terry Rosen	775,000	2,199,450	6,008,860	658,750	9,656,813
7	Sage Therapeutics	2024	Barry Greene	830,712	3,164,364	2,669,263	431,970	7,112,589
8	Zymeworks	2025	Kenneth Galbraith	656,763	2,538,240	2,366,565	340,990	6,613,180
9	Arvinas	2025	John Houston	706,236	2,685,840	2,671,051	457,000	6,534,127
10	Allogene Therapeutics	2025	David Chang	724,000	2,409,537	2,588,329	400,010	6,136,093
11	Replimune Group	2026	Sushil Patel	700,000	3,376,003	1,448,325	315,000	5,845,982
12	Intellia Therapeutics	2025	John Leonard	708,000	2,443,920	1,356,320	0	5,063,899
13	Denali Therapeutics	2025	Ryan Watts	718,000	1,151,867	2,180,003	0	4,751,515
14	Fate Therapeutics	2025	Bahram Valamehr	600,000	0	1,283,868	360,000	2,248,568
15	Alector	2025	Arnon Rosenthal	678,100	422,876	558,216	325,488	1,995,018

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Cerevel Therapeutics Holdings	128.8%	Options 100	not disclosed	Pay Governance LLC
Alector	80%	not disclosed	not disclosed	Pearl Meyer & Partners, LLC
Allogene Therapeutics	not disclosed	Option 55 · RSU 25 · PSU 20	not disclosed	Compensia
Arcus Biosciences	100%	Options 67 · RSU 33	not disclosed	Radford
Arvinas	108%	Options 50 · RSU 50	not disclosed	Aon (Aon's Human Capital Solutions practice, a division of Aon plc)
Axsome Therapeutics	150%	RSU 33 · Options 33 · PSU 33	No	Frederic W. Cook & Co., Inc.
BridgeBio Pharma	135%	RSU 50 · PSU 35 · Options 15	No	Aon Talent Solutions
Denali Therapeutics	145%	not disclosed	not disclosed	Alpine Rewards
Fate Therapeutics	100%	Options 100	No	Aon's Human Capital Solutions practice (Radford)
Intellia Therapeutics	115%	Option 40 · RSU 40 · PSU 20	Yes — TSR relative to the Nasdaq Biotechnology Index	Alpine
Karuna Therapeutics	145%	Option 100	not disclosed	Aon
Neurocrine Biosciences	105%	Option 50 · PRSU 30 · RSU 20	No	Frederic W. Cook & Co., Inc.
Replimune Group	not disclosed	not disclosed	No	Pearl Meyer
Sage Therapeutics	80%	not disclosed	Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index	Alpine Rewards
Zymeworks	not disclosed	Option 50 · RSU 50	not disclosed	Aon plc (Talent Solutions practice)

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2023	2023-06-07	148,773,111	606,133	4,381	99.59%	Passed
2022	2022-06-14	115,000,333	388,152	10,024	99.66%	Passed
2021	2021-06-10	—	—	—	—	—
2020	2020-10-26	—	—	—	—	—

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2023	2023-06-07	99.59%^a
2022	2022-06-14	99.66%^b
2021	2021-06-10	—^c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this vote.”.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	35 : 1
CEO total compensation	$11,225,426
Median employee compensation	—

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
PERCEPTIVE ADVISORS LLC	Director	2023-10-16	A	876,808	$23	$19,999,990	Common	Form 4 ↗
BAIN CAPITAL INVESTORS LLC	Greater-than-10% holder	2023-10-16	A	5,480,052	23	124,999,986	Common, indirect	Form 4 ↗
Adam Koppel	Director	2023-10-16	A	5,480,052	23	124,999,986	Common, indirect	Form 4 ↗
Christopher R. Gordon	Director	2023-10-16	A	5,480,052	23	124,999,986	Common, indirect	Form 4 ↗
Deval L. Patrick	Director	2023-11-01	D	30,130	0	0	Derivative, Class A Common	Form 4 ↗
Deval L. Patrick	Director	2023-11-01	D	30,130	25	753,250	Common	Form 4 ↗
Deval L. Patrick	Director	2023-11-01	A	30,130	13	380,241	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-02	D	38,599	25	972,239	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-02	D	38,599	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-02	A	38,599	4	135,097	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-03	D	61,401	25	1,561,458	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-03	A	61,401	4	214,904	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-03	D	61,401	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-07	D	27,076	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-07	D	27,076	25	677,555	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-07	A	27,076	4	94,766	Common	Form 4 ↗
Dividend-equivalent accruals		2023-11-08	—	100	—	—	1 insider, 1 accrual row
N. Anthony Coles	Director	2023-11-08	A	100	4	350	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-08	D	100	25	2,516	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-14	D	22,824	25	573,455	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-14	D	22,824	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-14	A	22,824	4	79,884	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-05	D	7,500	0	0	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-05	D	7,500	35	262,500	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-05	A	7,500	13	98,775	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-07	D	10,000	0	0	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-07	D	10,000	41	413,700	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-07	A	10,000	13	131,700	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-07	D	10,000	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-07	D	10,000	41	413,700	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-07	A	10,000	4	35,000	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-15	D	7,500	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-15	D	7,500	41	310,393	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-15	A	7,500	10	74,100	Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2023-12-19	D	13,804	0	0	Derivative, Class A Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2023-12-19	A	13,804	—	—	Common	Form 4 ↗
Mark Bodenrader	See Remarks	2023-12-19	D	5,085	0	0	Derivative, Class A Common	Form 4 ↗
Mark Bodenrader	See Remarks	2023-12-19	D	14,199	0	0	Derivative, Class A Common	Form 4 ↗
Mark Bodenrader	See Remarks	2023-12-19	A	5,085	—	—	Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2023-12-19	D	30,721	0	0	Derivative, Class A Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2023-12-19	A	30,721	—	—	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-19	D	24,825	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-19	A	24,825	—	—	Common	Form 4 ↗
Ronald C. Renaud JR	Director	2023-12-19	D	160,452	0	0	Derivative, Class A Common	Form 4 ↗
Ronald C. Renaud JR	Director	2023-12-19	A	160,452	—	—	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-19	D	13,796	0	0	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-19	A	13,796	—	—	Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-19	D	13,913	0	0	Derivative, Class A Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-19	A	13,913	—	—	Common	Form 4 ↗
Paul D. Burgess	See Remarks	2023-12-19	D	23,847	0	0	Derivative, Class A Common	Form 4 ↗
Paul D. Burgess	See Remarks	2023-12-19	A	23,847	—	—	Common	Form 4 ↗
Mark Bodenrader	See Remarks	2023-12-19	A	14,199	—	—	Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2023-12-20	D	6,288	41	260,469	Common	Form 4 ↗
Mark Bodenrader	See Remarks	2023-12-20	D	7,889	41	326,788	Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2023-12-20	D	13,808	41	571,972	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-20	D	10,152	41	420,528	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-20	D	7,072	41	292,945	Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-20	D	6,256	41	259,144	Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-22	D	8,000	0	0	Derivative, Class A Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-22	D	8,000	41	331,608	Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-22	A	8,000	4	28,000	Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2023-12-26	D	3,150	0	0	Derivative, Class A Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2023-12-26	A	3,150	10	31,658	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-26	D	10,000	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-26	D	10,000	42	424,700	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-26	A	10,000	4	35,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-01-02	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-01-02	D	50,000	42	2,111,815	Common	Form 4 ↗
N. Anthony Coles	Director	2024-01-02	A	50,000	4	175,000	Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2024-01-19	A	59,171	0	0	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2024-01-19	A	59,171	0	0	Derivative, Class A Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2024-01-19	A	81,065	0	0	Derivative, Class A Common	Form 4 ↗
Mark Bodenrader	See Remarks	2024-01-19	A	24,852	0	0	Derivative, Class A Common	Form 4 ↗
Paul D. Burgess	See Remarks	2024-01-19	A	81,065	0	0	Derivative, Class A Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-01-19	A	87,573	0	0	Derivative, Class A Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2024-01-19	A	63,905	0	0	Derivative, Class A Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-01-19	A	284,023	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2024-01-19	A	87,573	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-06	D	15,440	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-06	A	15,440	—	—	Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-02-06	D	5,020	0	0	Derivative, Class A Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-02-06	A	5,020	—	—	Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-07	D	2,506	42	104,110	Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-02-07	D	2,161	42	89,777	Common	Form 4 ↗
PERCEPTIVE ADVISORS LLC	Director	2024-02-20	D	170,317	0	0	Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-29	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-29	A	50,000	4	175,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-29	D	50,000	41	2,057,890	Common	Form 4 ↗
N. Anthony Coles	Director	2024-03-04	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-03-04	D	50,000	41	2,050,550	Common	Form 4 ↗
N. Anthony Coles	Director	2024-03-04	A	50,000	4	175,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-04-01	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-04-01	D	50,000	42	2,116,640	Common	Form 4 ↗
N. Anthony Coles	Director	2024-04-01	A	50,000	4	175,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-05-10	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-05-10	D	50,000	42	2,105,125	Common	Form 4 ↗
N. Anthony Coles	Director	2024-05-10	A	50,000	4	175,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-06-03	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-06-03	A	50,000	4	175,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-06-03	D	50,000	41	2,030,520	Common	Form 4 ↗
Ruth Mckernan	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Marijn E. Dekkers	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Adam Koppel	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Douglas E. Giordano	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Norbert G. Riedel	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Christopher R. Gordon	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Gabrielle Sulzberger	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Deval L. Patrick	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
N. Anthony Coles	Director	2024-06-05	A	10,290	—	—	Common	Form 4 ↗
N. Anthony Coles	Director	2024-07-01	D	25,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-07-01	D	25,000	41	1,029,535	Common	Form 4 ↗
N. Anthony Coles	Director	2024-07-01	A	25,000	4	87,500	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2024-08-01	D	59,171	0	0	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2024-08-01	D	367,126	—	—	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2024-08-01	D	7,527	—	—	Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2024-08-01	D	59,171	0	0	Derivative, Class A Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2024-08-01	D	614,428	—	—	Derivative, Class A Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2024-08-01	D	10,666	—	—	Common	Form 4 ↗
N. Anthony Coles	Director	2024-08-01	D	46,322	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-08-01	D	4,809,418	—	—	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-08-01	D	10,290	—	—	Common	Form 4 ↗
Mark Bodenrader	See Remarks	2024-08-01	D	24,852	0	0	Derivative, Class A Common	Form 4 ↗
Mark Bodenrader	See Remarks	2024-08-01	D	277,817	—	—	Derivative, Class A Common	Form 4 ↗
Mark Bodenrader	See Remarks	2024-08-01	D	17,724	—	—	Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-08-01	D	87,573	0	0	Derivative, Class A Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-08-01	D	15,061	0	0	Derivative, Class A Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-08-01	D	778,418	—	—	Derivative, Class A Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-08-01	D	6,370	—	—	Common	Form 4 ↗
N. Anthony Coles	Director	2024-08-01	D	15,638	—	—	Common	Form 4 ↗
Paul D. Burgess	See Remarks	2024-08-01	D	81,065	0	0	Derivative, Class A Common	Form 4 ↗
Paul D. Burgess	See Remarks	2024-08-01	D	95,931	—	—	Derivative, Class A Common	Form 4 ↗
Paul D. Burgess	See Remarks	2024-08-01	D	45,727	—	—	Common	Form 4 ↗
Deval L. Patrick	Director	2024-08-01	D	49,794	—	—	Derivative, Class A Common	Form 4 ↗
Deval L. Patrick	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Deval L. Patrick	Director	2024-08-01	D	3,282	—	—	Common	Form 4 ↗
Norbert G. Riedel	Director	2024-08-01	D	95,242	—	—	Derivative, Class A Common	Form 4 ↗
Norbert G. Riedel	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Norbert G. Riedel	Director	2024-08-01	D	46,092	—	—	Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2024-08-01	D	81,065	0	0	Derivative, Class A Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2024-08-01	D	124,168	—	—	Derivative, Class A Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2024-08-01	D	16,913	—	—	Common	Form 4 ↗
Marijn E. Dekkers	Director	2024-08-01	D	95,242	—	—	Derivative, Class A Common	Form 4 ↗
Marijn E. Dekkers	Director	2024-08-01	D	402,326	—	—	Common, indirect	Form 4 ↗
Marijn E. Dekkers	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Marijn E. Dekkers	Director	2024-08-01	D	31,822	—	—	Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2024-08-01	D	63,905	0	0	Derivative, Class A Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2024-08-01	D	711,827	—	—	Derivative, Class A Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2024-08-01	D	25,042	—	—	Common	Form 4 ↗
Gabrielle Sulzberger	Director	2024-08-01	D	95,242	—	—	Derivative, Class A Common	Form 4 ↗
Gabrielle Sulzberger	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Gabrielle Sulzberger	Director	2024-08-01	D	48,415	—	—	Common	Form 4 ↗
Ruth Mckernan	Director	2024-08-01	D	92,986	—	—	Derivative, Class A Common	Form 4 ↗
Ruth Mckernan	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Ruth Mckernan	Director	2024-08-01	D	3,282	—	—	Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-08-01	D	320,742	0	0	Derivative, Class A Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-08-01	D	284,023	0	0	Derivative, Class A Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-08-01	D	215,749	—	—	Derivative, Class A Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-08-01	D	83,857	—	—	Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-08-01	D	160,452	—	—	Common	Form 4 ↗
Douglas E. Giordano	Director	2024-08-01	D	95,242	—	—	Derivative, Class A Common	Form 4 ↗
Douglas E. Giordano	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Douglas E. Giordano	Director	2024-08-01	D	3,282	—	—	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2024-08-01	D	87,573	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2024-08-01	D	1,393,153	—	—	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2024-08-01	D	14,673	—	—	Common	Form 4 ↗
Adam Koppel	Director	2024-08-01	D	80,189	—	—	Derivative, Class A Common	Form 4 ↗
Adam Koppel	Director	2024-08-01	D	65,679,781	—	—	Common, indirect	Form 4 ↗
Adam Koppel	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Adam Koppel	Director	2024-08-01	D	3,282	—	—	Common	Form 4 ↗
Christopher R. Gordon	Director	2024-08-01	D	80,189	—	—	Derivative, Class A Common	Form 4 ↗
Christopher R. Gordon	Director	2024-08-01	D	65,679,781	—	—	Common, indirect	Form 4 ↗
Christopher R. Gordon	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Christopher R. Gordon	Director	2024-08-01	D	3,282	—	—	Common	Form 4 ↗
BAIN CAPITAL INVESTORS LLC	Director	2024-08-01	D	65,679,781	—	—	Common, indirect	Form 4 ↗
PFIZER INC	—	2024-08-01	D	27,349,211	45	1,230,714,495	Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 175 transactions

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
PERCEPTIVE ADVISORS LLC	Director	2023-10-16	A	876,808	$23	$19,999,990	Common	Form 4 ↗
BAIN CAPITAL INVESTORS LLC	Greater-than-10% holder	2023-10-16	A	5,480,052	23	124,999,986	Common, indirect	Form 4 ↗
Adam Koppel	Director	2023-10-16	A	5,480,052	23	124,999,986	Common, indirect	Form 4 ↗
Christopher R. Gordon	Director	2023-10-16	A	5,480,052	23	124,999,986	Common, indirect	Form 4 ↗
Deval L. Patrick	Director	2023-11-01	D	30,130	0	0	Derivative, Class A Common	Form 4 ↗
Deval L. Patrick	Director	2023-11-01	D	30,130	25	753,250	Common	Form 4 ↗
Deval L. Patrick	Director	2023-11-01	A	30,130	13	380,241	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-02	D	38,599	25	972,239	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-02	D	38,599	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-02	A	38,599	4	135,097	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-03	D	61,401	25	1,561,458	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-03	A	61,401	4	214,904	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-03	D	61,401	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-07	D	27,076	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-07	D	27,076	25	677,555	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-07	A	27,076	4	94,766	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-08	D	100	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-08	A	100	4	350	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-08	D	100	25	2,516	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-14	D	22,824	25	573,455	Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-14	D	22,824	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2023-11-14	A	22,824	4	79,884	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-05	D	7,500	0	0	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-05	D	7,500	35	262,500	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-05	A	7,500	13	98,775	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-07	D	10,000	0	0	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-07	D	10,000	41	413,700	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-07	A	10,000	13	131,700	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-07	D	10,000	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-07	D	10,000	41	413,700	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-07	A	10,000	4	35,000	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-15	D	7,500	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-15	D	7,500	41	310,393	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-15	A	7,500	10	74,100	Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2023-12-19	D	13,804	0	0	Derivative, Class A Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2023-12-19	A	13,804	—	—	Common	Form 4 ↗
Mark Bodenrader	See Remarks	2023-12-19	D	5,085	0	0	Derivative, Class A Common	Form 4 ↗
Mark Bodenrader	See Remarks	2023-12-19	D	14,199	0	0	Derivative, Class A Common	Form 4 ↗
Mark Bodenrader	See Remarks	2023-12-19	A	5,085	—	—	Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2023-12-19	D	30,721	0	0	Derivative, Class A Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2023-12-19	A	30,721	—	—	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-19	D	24,825	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-19	A	24,825	—	—	Common	Form 4 ↗
Ronald C. Renaud JR	Director	2023-12-19	D	160,452	0	0	Derivative, Class A Common	Form 4 ↗
Ronald C. Renaud JR	Director	2023-12-19	A	160,452	—	—	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-19	D	13,796	0	0	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-19	A	13,796	—	—	Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-19	D	13,913	0	0	Derivative, Class A Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-19	A	13,913	—	—	Common	Form 4 ↗
Paul D. Burgess	See Remarks	2023-12-19	D	23,847	0	0	Derivative, Class A Common	Form 4 ↗
Paul D. Burgess	See Remarks	2023-12-19	A	23,847	—	—	Common	Form 4 ↗
Mark Bodenrader	See Remarks	2023-12-19	A	14,199	—	—	Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2023-12-20	D	6,288	41	260,469	Common	Form 4 ↗
Mark Bodenrader	See Remarks	2023-12-20	D	7,889	41	326,788	Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2023-12-20	D	13,808	41	571,972	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-20	D	10,152	41	420,528	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2023-12-20	D	7,072	41	292,945	Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-20	D	6,256	41	259,144	Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-22	D	8,000	0	0	Derivative, Class A Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-22	D	8,000	41	331,608	Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2023-12-22	A	8,000	4	28,000	Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2023-12-26	D	3,150	0	0	Derivative, Class A Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2023-12-26	A	3,150	10	31,658	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-26	D	10,000	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-26	D	10,000	42	424,700	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2023-12-26	A	10,000	4	35,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-01-02	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-01-02	D	50,000	42	2,111,815	Common	Form 4 ↗
N. Anthony Coles	Director	2024-01-02	A	50,000	4	175,000	Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2024-01-19	A	59,171	0	0	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2024-01-19	A	59,171	0	0	Derivative, Class A Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2024-01-19	A	81,065	0	0	Derivative, Class A Common	Form 4 ↗
Mark Bodenrader	See Remarks	2024-01-19	A	24,852	0	0	Derivative, Class A Common	Form 4 ↗
Paul D. Burgess	See Remarks	2024-01-19	A	81,065	0	0	Derivative, Class A Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-01-19	A	87,573	0	0	Derivative, Class A Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2024-01-19	A	63,905	0	0	Derivative, Class A Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-01-19	A	284,023	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2024-01-19	A	87,573	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-06	D	15,440	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-06	A	15,440	—	—	Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-02-06	D	5,020	0	0	Derivative, Class A Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-02-06	A	5,020	—	—	Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-07	D	2,506	42	104,110	Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-02-07	D	2,161	42	89,777	Common	Form 4 ↗
PERCEPTIVE ADVISORS LLC	Director	2024-02-20	D	170,317	0	0	Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-29	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-29	A	50,000	4	175,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-02-29	D	50,000	41	2,057,890	Common	Form 4 ↗
N. Anthony Coles	Director	2024-03-04	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-03-04	D	50,000	41	2,050,550	Common	Form 4 ↗
N. Anthony Coles	Director	2024-03-04	A	50,000	4	175,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-04-01	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-04-01	D	50,000	42	2,116,640	Common	Form 4 ↗
N. Anthony Coles	Director	2024-04-01	A	50,000	4	175,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-05-10	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-05-10	D	50,000	42	2,105,125	Common	Form 4 ↗
N. Anthony Coles	Director	2024-05-10	A	50,000	4	175,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-06-03	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-06-03	A	50,000	4	175,000	Common	Form 4 ↗
N. Anthony Coles	Director	2024-06-03	D	50,000	41	2,030,520	Common	Form 4 ↗
Ruth Mckernan	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Marijn E. Dekkers	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Adam Koppel	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Douglas E. Giordano	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Norbert G. Riedel	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Christopher R. Gordon	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Gabrielle Sulzberger	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
Deval L. Patrick	Director	2024-06-05	A	10,461	—	—	Common	Form 4 ↗
N. Anthony Coles	Director	2024-06-05	A	10,290	—	—	Common	Form 4 ↗
N. Anthony Coles	Director	2024-07-01	D	25,000	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-07-01	D	25,000	41	1,029,535	Common	Form 4 ↗
N. Anthony Coles	Director	2024-07-01	A	25,000	4	87,500	Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2024-08-01	D	59,171	0	0	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2024-08-01	D	367,126	—	—	Derivative, Class A Common	Form 4 ↗
Scott Akamine	Chief Legal Officer	2024-08-01	D	7,527	—	—	Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2024-08-01	D	59,171	0	0	Derivative, Class A Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2024-08-01	D	614,428	—	—	Derivative, Class A Common	Form 4 ↗
Kathleen Tregoning	See Remarks	2024-08-01	D	10,666	—	—	Common	Form 4 ↗
N. Anthony Coles	Director	2024-08-01	D	46,322	0	0	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-08-01	D	4,809,418	—	—	Derivative, Class A Common	Form 4 ↗
N. Anthony Coles	Director	2024-08-01	D	10,290	—	—	Common	Form 4 ↗
Mark Bodenrader	See Remarks	2024-08-01	D	24,852	0	0	Derivative, Class A Common	Form 4 ↗
Mark Bodenrader	See Remarks	2024-08-01	D	277,817	—	—	Derivative, Class A Common	Form 4 ↗
Mark Bodenrader	See Remarks	2024-08-01	D	17,724	—	—	Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-08-01	D	87,573	0	0	Derivative, Class A Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-08-01	D	15,061	0	0	Derivative, Class A Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-08-01	D	778,418	—	—	Derivative, Class A Common	Form 4 ↗
John Renger	Chief Scientific Officer	2024-08-01	D	6,370	—	—	Common	Form 4 ↗
N. Anthony Coles	Director	2024-08-01	D	15,638	—	—	Common	Form 4 ↗
Paul D. Burgess	See Remarks	2024-08-01	D	81,065	0	0	Derivative, Class A Common	Form 4 ↗
Paul D. Burgess	See Remarks	2024-08-01	D	95,931	—	—	Derivative, Class A Common	Form 4 ↗
Paul D. Burgess	See Remarks	2024-08-01	D	45,727	—	—	Common	Form 4 ↗
Deval L. Patrick	Director	2024-08-01	D	49,794	—	—	Derivative, Class A Common	Form 4 ↗
Deval L. Patrick	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Deval L. Patrick	Director	2024-08-01	D	3,282	—	—	Common	Form 4 ↗
Norbert G. Riedel	Director	2024-08-01	D	95,242	—	—	Derivative, Class A Common	Form 4 ↗
Norbert G. Riedel	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Norbert G. Riedel	Director	2024-08-01	D	46,092	—	—	Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2024-08-01	D	81,065	0	0	Derivative, Class A Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2024-08-01	D	124,168	—	—	Derivative, Class A Common	Form 4 ↗
Susan ALTSCHULLER	Chief Financial Officer	2024-08-01	D	16,913	—	—	Common	Form 4 ↗
Marijn E. Dekkers	Director	2024-08-01	D	95,242	—	—	Derivative, Class A Common	Form 4 ↗
Marijn E. Dekkers	Director	2024-08-01	D	402,326	—	—	Common, indirect	Form 4 ↗
Marijn E. Dekkers	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Marijn E. Dekkers	Director	2024-08-01	D	31,822	—	—	Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2024-08-01	D	63,905	0	0	Derivative, Class A Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2024-08-01	D	711,827	—	—	Derivative, Class A Common	Form 4 ↗
Kenneth DiPietro	Chief Human Resources Officer	2024-08-01	D	25,042	—	—	Common	Form 4 ↗
Gabrielle Sulzberger	Director	2024-08-01	D	95,242	—	—	Derivative, Class A Common	Form 4 ↗
Gabrielle Sulzberger	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Gabrielle Sulzberger	Director	2024-08-01	D	48,415	—	—	Common	Form 4 ↗
Ruth Mckernan	Director	2024-08-01	D	92,986	—	—	Derivative, Class A Common	Form 4 ↗
Ruth Mckernan	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Ruth Mckernan	Director	2024-08-01	D	3,282	—	—	Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-08-01	D	320,742	0	0	Derivative, Class A Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-08-01	D	284,023	0	0	Derivative, Class A Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-08-01	D	215,749	—	—	Derivative, Class A Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-08-01	D	83,857	—	—	Common	Form 4 ↗
Ronald C. Renaud JR	Director	2024-08-01	D	160,452	—	—	Common	Form 4 ↗
Douglas E. Giordano	Director	2024-08-01	D	95,242	—	—	Derivative, Class A Common	Form 4 ↗
Douglas E. Giordano	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Douglas E. Giordano	Director	2024-08-01	D	3,282	—	—	Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2024-08-01	D	87,573	0	0	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2024-08-01	D	1,393,153	—	—	Derivative, Class A Common	Form 4 ↗
Raymond Sanchez	Chief Medical Officer	2024-08-01	D	14,673	—	—	Common	Form 4 ↗
Adam Koppel	Director	2024-08-01	D	80,189	—	—	Derivative, Class A Common	Form 4 ↗
Adam Koppel	Director	2024-08-01	D	65,679,781	—	—	Common, indirect	Form 4 ↗
Adam Koppel	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Adam Koppel	Director	2024-08-01	D	3,282	—	—	Common	Form 4 ↗
Christopher R. Gordon	Director	2024-08-01	D	80,189	—	—	Derivative, Class A Common	Form 4 ↗
Christopher R. Gordon	Director	2024-08-01	D	65,679,781	—	—	Common, indirect	Form 4 ↗
Christopher R. Gordon	Director	2024-08-01	D	10,461	—	—	Common	Form 4 ↗
Christopher R. Gordon	Director	2024-08-01	D	3,282	—	—	Common	Form 4 ↗
BAIN CAPITAL INVESTORS LLC	Director	2024-08-01	D	65,679,781	—	—	Common, indirect	Form 4 ↗
PFIZER INC	—	2024-08-01	D	27,349,211	45	1,230,714,495	Common	Form 4 ↗

Sources (222 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, N. Anthony Coles. DEF 14A, filed 2023-04-28. Section “Summary Compensation Table” · page 33. As printed: 11,225,426. View filing ↗
Section 01, Raymond Sanchez. DEF 14A, filed 2023-04-28. Section “Summary Compensation Table” · page 33. As printed: 4,805,110. View filing ↗
Section 01, John Renger. DEF 14A, filed 2023-04-28. Section “Summary Compensation Table” · page 33. As printed: 4,779,729. View filing ↗
Section 01, Abraham Ceesay. DEF 14A, filed 2023-04-28. Section “Summary Compensation Table” · page 33. As printed: 3,676,491. View filing ↗
Section 01, Mark Bodenrader. DEF 14A, filed 2023-04-28. Section “Summary Compensation Table” · page 33. As printed: 1,583,640. View filing ↗
Section 03, Mark Bodenrader OPTION. DEF 14A, filed 2023-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Mark Bodenrader RSU. DEF 14A, filed 2023-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Raymond Sanchez OPTION. DEF 14A, filed 2023-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Abraham Ceesay OPTION. DEF 14A, filed 2023-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, John Renger OPTION. DEF 14A, filed 2023-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, N. Anthony OPTION. DEF 14A, filed 2023-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A. Section “CEO Pay Ratio”. As printed: 35 : 1.
Section 08, Norbert Riedel, Ph.D. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 562,566. View filing ↗
Section 08, Gabrielle Sulzberger, J.D., M.B.A. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 510,983. View filing ↗
Section 08, Marijn Dekkers, Ph.D. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 499,317. View filing ↗
Section 08, Doug Giordano, M.B.A. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 497,150. View filing ↗
Section 08, Christopher Gordon, M.B.A. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 497,150. View filing ↗
Section 08, Adam Koppel, M.D., Ph.D. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 492,984. View filing ↗
Section 08, Ruth McKernan, Ph.D., CBE, FMedSci. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 485,484. View filing ↗
Section 08, Deval Patrick, J.D. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 485,484. View filing ↗
Section 08, Suneet Varma, M.B.A. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
Section 08, Deborah Baron, M.B.A. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
Section 08, N. Anthony Coles, M.D. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
Section 08, Morris Birnbaum, M.D., Ph.D. DEF 14A, filed 2023-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
Section 02, PERCEPTIVE ADVISORS LLC 2023-10-16. Form 4, filed 2023-10-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAIN CAPITAL INVESTORS LLC 2023-10-16. Form 4, filed 2023-10-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Adam Koppel 2023-10-16. Form 4, filed 2023-10-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher R. Gordon 2023-10-16. Form 4, filed 2023-10-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Deval L. Patrick 2023-11-01. Form 4, filed 2023-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Deval L. Patrick 2023-11-01. Form 4, filed 2023-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Deval L. Patrick 2023-11-01. Form 4, filed 2023-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-02. Form 4, filed 2023-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-02. Form 4, filed 2023-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-02. Form 4, filed 2023-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-03. Form 4, filed 2023-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-03. Form 4, filed 2023-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-03. Form 4, filed 2023-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-07. Form 4, filed 2023-11-09. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-07. Form 4, filed 2023-11-09. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-07. Form 4, filed 2023-11-09. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-08. Form 4, filed 2023-11-09. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-08. Form 4, filed 2023-11-09. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-08. Form 4, filed 2023-11-09. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-14. Form 4, filed 2023-11-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-14. Form 4, filed 2023-11-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2023-11-14. Form 4, filed 2023-11-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2023-12-05. Form 4, filed 2023-12-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2023-12-05. Form 4, filed 2023-12-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2023-12-05. Form 4, filed 2023-12-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2023-12-07. Form 4, filed 2023-12-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2023-12-07. Form 4, filed 2023-12-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2023-12-07. Form 4, filed 2023-12-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-07. Form 4, filed 2023-12-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-07. Form 4, filed 2023-12-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-07. Form 4, filed 2023-12-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-15. Form 4, filed 2023-12-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-15. Form 4, filed 2023-12-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-15. Form 4, filed 2023-12-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathleen Tregoning 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathleen Tregoning 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Bodenrader 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Bodenrader 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Bodenrader 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan ALTSCHULLER 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan ALTSCHULLER 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ronald C. Renaud JR 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ronald C. Renaud JR 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kenneth DiPietro 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kenneth DiPietro 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Paul D. Burgess 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Paul D. Burgess 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Bodenrader 2023-12-19. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathleen Tregoning 2023-12-20. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Bodenrader 2023-12-20. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan ALTSCHULLER 2023-12-20. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-20. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2023-12-20. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kenneth DiPietro 2023-12-20. Form 4, filed 2023-12-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kenneth DiPietro 2023-12-22. Form 4, filed 2023-12-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kenneth DiPietro 2023-12-22. Form 4, filed 2023-12-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kenneth DiPietro 2023-12-22. Form 4, filed 2023-12-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathleen Tregoning 2023-12-26. Form 4, filed 2023-12-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathleen Tregoning 2023-12-26. Form 4, filed 2023-12-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-26. Form 4, filed 2023-12-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-26. Form 4, filed 2023-12-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2023-12-26. Form 4, filed 2023-12-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-01-02. Form 4, filed 2024-01-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-01-02. Form 4, filed 2024-01-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-01-02. Form 4, filed 2024-01-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathleen Tregoning 2024-01-19. Form 4, filed 2024-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2024-01-19. Form 4, filed 2024-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan ALTSCHULLER 2024-01-19. Form 4, filed 2024-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Bodenrader 2024-01-19. Form 4, filed 2024-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Paul D. Burgess 2024-01-19. Form 4, filed 2024-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Renger 2024-01-19. Form 4, filed 2024-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kenneth DiPietro 2024-01-19. Form 4, filed 2024-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ronald C. Renaud JR 2024-01-19. Form 4, filed 2024-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2024-01-19. Form 4, filed 2024-01-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-02-06. Form 4, filed 2024-02-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-02-06. Form 4, filed 2024-02-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Renger 2024-02-06. Form 4, filed 2024-02-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Renger 2024-02-06. Form 4, filed 2024-02-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-02-07. Form 4, filed 2024-02-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Renger 2024-02-07. Form 4, filed 2024-02-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, PERCEPTIVE ADVISORS LLC 2024-02-20. Form 4, filed 2024-02-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-02-29. Form 4, filed 2024-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-02-29. Form 4, filed 2024-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-02-29. Form 4, filed 2024-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-03-04. Form 4, filed 2024-03-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-03-04. Form 4, filed 2024-03-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-03-04. Form 4, filed 2024-03-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-04-01. Form 4, filed 2024-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-04-01. Form 4, filed 2024-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-04-01. Form 4, filed 2024-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-05-10. Form 4, filed 2024-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-05-10. Form 4, filed 2024-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-05-10. Form 4, filed 2024-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-06-03. Form 4, filed 2024-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-06-03. Form 4, filed 2024-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-06-03. Form 4, filed 2024-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ruth Mckernan 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marijn E. Dekkers 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Adam Koppel 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Douglas E. Giordano 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Norbert G. Riedel 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher R. Gordon 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gabrielle Sulzberger 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Deval L. Patrick 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Scott Akamine 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathleen Tregoning 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathleen Tregoning 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathleen Tregoning 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Bodenrader 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Bodenrader 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Mark Bodenrader 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Renger 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Renger 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Renger 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Renger 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, N. Anthony Coles 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Paul D. Burgess 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Paul D. Burgess 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Paul D. Burgess 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Deval L. Patrick 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Deval L. Patrick 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Deval L. Patrick 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Norbert G. Riedel 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Norbert G. Riedel 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Norbert G. Riedel 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan ALTSCHULLER 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan ALTSCHULLER 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan ALTSCHULLER 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marijn E. Dekkers 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marijn E. Dekkers 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marijn E. Dekkers 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marijn E. Dekkers 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kenneth DiPietro 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kenneth DiPietro 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kenneth DiPietro 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gabrielle Sulzberger 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gabrielle Sulzberger 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gabrielle Sulzberger 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ruth Mckernan 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ruth Mckernan 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ruth Mckernan 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ronald C. Renaud JR 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ronald C. Renaud JR 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ronald C. Renaud JR 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ronald C. Renaud JR 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ronald C. Renaud JR 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Douglas E. Giordano 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Douglas E. Giordano 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Douglas E. Giordano 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Raymond Sanchez 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Adam Koppel 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Adam Koppel 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Adam Koppel 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Adam Koppel 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher R. Gordon 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher R. Gordon 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher R. Gordon 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher R. Gordon 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAIN CAPITAL INVESTORS LLC 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, PFIZER INC 2024-08-01. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2023 vote. Form 8-K, filed 2023-06-08. Item 5.07 · say-on-pay result. As reported: 99.59% (votes for as printed: 148,773,111). View filing ↗
Section 06, 2022 vote. Form 8-K, filed 2022-06-15. Item 5.07 · say-on-pay result. As reported: 99.66% (votes for as printed: 115,000,333). View filing ↗
Section 06, 2021 vote. Form 8-K, filed 2021-06-16. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 607,246 + equity 0 + all other 0 = 607,246, summed across the director compensation table rows.
BridgeBio Pharma, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. View filing ↗
Neurocrine Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. View filing ↗
Cerevel Therapeutics Holdings (subject), Section 10b CEO total. DEF 14A, filed 2023-04-28. CEO total compensation as printed in Cerevel Therapeutics Holdings's own proxy. As printed: 11,225,426. View filing ↗
Karuna Therapeutics, Section 10b CEO total. DEF 14A, filed 2023-04-27. CEO total compensation as printed in Karuna Therapeutics's own proxy. As printed: 11,224,103. View filing ↗
Axsome Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Axsome Therapeutics's own proxy. As printed: 10,283,492. View filing ↗
Arcus Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. View filing ↗
Sage Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. View filing ↗
Zymeworks, Section 10b CEO total. DEF 14A, filed 2026-10-26. CEO total compensation as printed in Zymeworks's own proxy. As printed: 6,613,180. View filing ↗
Arvinas, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. View filing ↗
Allogene Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. View filing ↗
Replimune Group, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. View filing ↗
Intellia Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Intellia Therapeutics's own proxy. As printed: 5,063,899. View filing ↗
Denali Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. View filing ↗
Fate Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Fate Therapeutics's own proxy. As printed: 2,248,568. View filing ↗
Alector, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. View filing ↗
Section 10a, Karuna Therapeutics reciprocity. DEF 14A. Karuna Therapeutics names Cerevel Therapeutics Holdings in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Sage Therapeutics reciprocity. DEF 14A. Sage Therapeutics names Cerevel Therapeutics Holdings in its own disclosed peer group (read from its most recent proxy). View filing ↗